VICO Stock Overview
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Vicore Pharma Holding AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr15.00 |
52 Week High | kr26.90 |
52 Week Low | kr12.36 |
Beta | 0.78 |
1 Month Change | 10.46% |
3 Month Change | 3.73% |
1 Year Change | -7.75% |
3 Year Change | -43.40% |
5 Year Change | -9.64% |
Change since IPO | 111.27% |
Recent News & Updates
Recent updates
Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans
Feb 10We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
Sep 21We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
May 25Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)
Jan 10Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?
Nov 13Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation
Jul 26Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?
Mar 03What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition
Jan 11Shareholder Returns
VICO | SE Biotechs | SE Market | |
---|---|---|---|
7D | -5.5% | 1.4% | 1.8% |
1Y | -7.7% | 6.3% | 19.0% |
Return vs Industry: VICO underperformed the Swedish Biotechs industry which returned 6.3% over the past year.
Return vs Market: VICO underperformed the Swedish Market which returned 19% over the past year.
Price Volatility
VICO volatility | |
---|---|
VICO Average Weekly Movement | 6.7% |
Biotechs Industry Average Movement | 8.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in SE Market | 12.7% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: VICO has not had significant price volatility in the past 3 months.
Volatility Over Time: VICO's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 24 | Ahmed Mousa | https://www.vicorepharma.com |
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company’s portfolio includes idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) diseases. The company develops C21, a low molecular weight angiotensin II type 2 receptor agonist ATRAG; Almee, an investigational medical device in clinical development to address the psychological impact of living with pulmonary fibrosis; Inhaled IMID for the severe cough associated with IPF; and C103, C111, and C112.
Vicore Pharma Holding AB (publ) Fundamentals Summary
VICO fundamental statistics | |
---|---|
Market cap | kr1.68b |
Earnings (TTM) | -kr310.94m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs VICO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VICO income statement (TTM) | |
---|---|
Revenue | kr0 |
Cost of Revenue | kr0 |
Gross Profit | kr0 |
Other Expenses | kr310.94m |
Earnings | -kr310.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
Earnings per share (EPS) | -2.78 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did VICO perform over the long term?
See historical performance and comparison